Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sara Miano"'
Autor:
Ymera Pignochino, Federica Capozzi, Lorenzo D’Ambrosio, Carmine Dell’Aglio, Marco Basiricò, Marta Canta, Annalisa Lorenzato, Francesca Vignolo Lutati, Sandra Aliberti, Erica Palesandro, Paola Boccone, Danilo Galizia, Sara Miano, Giulia Chiabotto, Lucia Napione, Loretta Gammaitoni, Dario Sangiolo, Maria Serena Benassi, Barbara Pasini, Giovanna Chiorino, Massimo Aglietta, Giovanni Grignani
Publikováno v:
Molecular Cancer, Vol 16, Iss 1, Pp 1-15 (2017)
Abstract Background Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groo
Externí odkaz:
https://doaj.org/article/e058c6685da841f684afb510424d766a
Autor:
Francesco Tolomeo, Massimo Aglietta, Sandra Aliberti, Giovanni Grignani, Sara Miano, Alessandra Merlini
We report the case of a 51 year-old patient affected by an advanced uterine leiomyosarcoma treated with eribulin as fourth-line therapy. The patient, with a previous history of leiomyomas of the myometrium, had undergone total hysterectomy for repeat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f473b03f879213c8cdf94b379b50ba
http://hdl.handle.net/2318/1723160
http://hdl.handle.net/2318/1723160
Autor:
Giovanni Grignani, Dario Sangiolo, Lorenzo D’Ambrosio, Sara Miano, Francesco Tolomeo, Alessandra Merlini
Publikováno v:
Cancer Breaking News. 5:22-32
The introduction of immune checkpoint inhibitors represented a true revolution in the treatment of melanoma and a few other cancer subtypes. Unfortunately, the use of these drugs did not achieve the same beneficial results in other neoplasms, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caed9c93671f65bf5740bf5a3254f747
https://doi.org/10.19156/cbn.2017.0045
https://doi.org/10.19156/cbn.2017.0045
Autor:
Lorenzo D'Ambrosio, Giacomo Giulio Baldi, Francesco Tolomeo, Sandra Aliberti, Paola Boccone, Giovanni Grignani, Letizia Laera, Sara Miano
Publikováno v:
Cancer Breaking News. 4:30-35
Background Pazopanib is a multikinase inhibitor registered for the treatment of advanced renal clear cell carcinoma (RCC) and as second or further-line therapy in advanced non-adipocytic soft tissue sarcoma (STS). It is a relatively well-tolerated co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::192acd07575c2acd06a8ede5f0cfc809
https://doi.org/10.19156/cbn.2016.0026
https://doi.org/10.19156/cbn.2016.0026
Autor:
Paola Boccone, Ilaria Bertotto, Pietro Pellegrino, Raimondo Piana, Alberto Pisacane, Lorenzo D'Ambrosio, Sara Miano, Antonio Manca, Piotr Rutkowski, Giovanni Grignani
Publikováno v:
Cancer Breaking News. 4:36-41
Giant cell tumor (GCT) of the bone is a benign but locally aggressive tumor arising in the bones. The sacrum represents the most common involved site of the spine. At this level GCT might cause relevant neurological deficits and/or impair activities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c59791ff54f939cf62e70064b2195ff
https://doi.org/10.19156/cbn.2016.0027
https://doi.org/10.19156/cbn.2016.0027
Autor:
Lorenzo D'Ambrosio, Massimo Aglietta, Giovanni Grignani, Franziska Kubatzki, Dimitrios Siatis, Nicoletta Biglia, Sara Miano, Alberto Pisacane, Sandra Aliberti, L. Sgro, Giovanna Chilà, Francesco Tolomeo, Marco Gatti, Paola Sgandurra, Riccardo Ponzone, Alessandra Merlini, Giulia Manessi
Publikováno v:
Journal of Clinical Oncology. 38:e23546-e23546
e23546 Background: Although sarcomas may arise in any site of the body, the intrinsic challenge of BS is to affect the female most frequent cancer site with a completely different and rare set of heterogeneous tumors. Unfortunately, we lack BS-specif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::480e8ad72087b4e5138a737431ce2c09
https://doi.org/10.1200/jco.2020.38.15_suppl.e23546
https://doi.org/10.1200/jco.2020.38.15_suppl.e23546
Autor:
Angelo Paolo Dei Tos, Rossella Bertulli, Alberto Pisacane, Dario Sangiolo, Stefano Ferrari, Massimo Aglietta, Francesco Tolomeo, Lorenzo D'Ambrosio, Luca Novara, Sandra Aliberti, R. Piana, Giovanni Grignani, Emanuela Marchesi, Giulia Chiabotto, Maurizio D'Incalci, Paola Boccone, Alice Bartolini, Alberto Bardelli, Emanuela Palmerini, Sara Miano, Silvia Stacchiotti, Massimo Zucchetti, Piero Picci, Ymera Pignochino
Summary Background Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78da60dd3ec41f959b0a92e8b7dc0224
http://hdl.handle.net/2318/1678537
http://hdl.handle.net/2318/1678537
Autor:
Lucia Napione, Maria Serena Benassi, Giovanna Chiorino, Ymera Pignochino, Loretta Gammaitoni, Giovanni Grignani, Danilo Galizia, Erica Palesandro, Lorenzo D'Ambrosio, Marta Canta, Sandra Aliberti, Carmine Dell'Aglio, Barbara Pasini, Giulia Chiabotto, Francesca Vignolo Lutati, Annalisa Lorenzato, Marco Basiricò, Dario Sangiolo, Massimo Aglietta, Paola Boccone, Federica Capozzi, Sara Miano
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 16, Iss 1, Pp 1-15 (2017)
Molecular Cancer, Vol 16, Iss 1, Pp 1-15 (2017)
Background Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bac95fcb4d78dfaa034b6b64a689629
http://hdl.handle.net/2318/1636100
http://hdl.handle.net/2318/1636100
Autor:
Giulia Mesiano, Carmine Dell'Aglio, Cristina Cammarata, Alberto Pisacane, Andrea Bertotti, Ymera Pignochino, Sara Miano, Lidia Giraudo, Lorenzo D'Ambrosio, Wanda Piacibello, Loretta Gammaitoni, Ivana Ferrero, Valeria Leuci, Fabrizio Carnevale-Schianca, Massimo Aglietta, Ivana Sarotto, Maja Todorovic, Giovanni Grignani, Francesco Sassi, Franca Fagioli, Dario Sangiolo
Publikováno v:
Cancer Research. 74:119-129
Unresectable metastatic bone sarcoma and soft-tissue sarcomas (STS) are incurable due to the inability to eradicate chemoresistant cancer stem–like cells (sCSC) that are likely responsible for relapses and drug resistance. In this study, we investi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c742e9307b0c532071b71fe961b746c0
https://doi.org/10.1158/0008-5472.can-13-1559
https://doi.org/10.1158/0008-5472.can-13-1559
Autor:
Ilaria Bertotto, Alessandro Comandone, Giovanni Grignani, Sara Miano, Raimondo Piana, Alessandra Merlini, Sandra Aliberti, Lorenzo D'Ambrosio, G. Cattari, Marco Gatti, Giulia Manessi, Antonia Salatino, Tiziana Robba, Laura Rossi, Antonella Boglione, Monica Rampino, Francesco Tolomeo, Anna Mussano, Massimo Aglietta
Publikováno v:
Journal of Clinical Oncology. 37:e22508-e22508
e22508 Background: Advanced OS still represents an unmet medical need. Chemotherapy and targeted therapies have only limited activity in this disease. Moreover, OS is considered a radioresistant tumor at doses conventionally achieved by EBRT. We retr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b09a2e3b1a4edcd796006d7f1d659b3
https://doi.org/10.1200/jco.2019.37.15_suppl.e22508
https://doi.org/10.1200/jco.2019.37.15_suppl.e22508